Hypothesis

Restoring gut barrier integrity with the gastric‑derived peptide BPC-157 shifts the gut‑brain axis toward a protective, gut‑to‑brain direction, lowering systemic endotoxin and microglial activation while enhancing CNS autophagy and longevity pathways.

Mechanistic Rationale

BPC-157, originally isolated from human gastric juice, accelerates epithelial restitution and tight‑junction assembly [2]. A sealed gut lumen reduces translocation of lipopolysaccharide (LPS) and other pathogen‑associated molecular patterns, thereby decreasing chronic low‑grade inflammation that drives microglial NF‑κB signaling and mTORC1 activation in the brain [1]. Concurrently, an intact epithelium preserves enteroendocrine L‑cell function, allowing age‑declining GLP-1 and peptide YY secretion to reach the circulation and activate vagal afferents that promote hippocampal neurogenesis and FOXO3‑mediated autophagy [1]. Thus, BPC‑157’s primary anti‑aging action may be indirect: by fixing the gut first, it permits endogenous gut‑derived signals to set a youthful brain homeostasis.

Testable Predictions

1. Chronic low‑dose BPC-157 supplementation in aged mice will decrease serum LPS‑binding protein and intestinal permeability (FITC-dextran assay) compared with vehicle.
2. Reduced endotoxemia will correlate with lower brain IL-1β, TNF-α, and phospho‑S6K (mTORC1 read‑out) levels, alongside increased LC3-II/I ratio and SIRT1 activity in the hippocampus.
3. Mice receiving BPC-157 will exhibit extended median lifespan and improved performance on rotarod and Morris water maze tasks relative to controls.
4. Depleting the gut microbiota with broad‑spectrum antibiotics will abolish the longevity benefit of BPC-157, confirming that the effect depends on microbiota‑derived metabolites (e.g., SCFAs) that act downstream of barrier repair.

Experimental Design

• Animals: 20‑month‑old C57BL/6J mice, n=30 per group (BPC-157, vehicle, antibiotic‑plus‑BPC-157, antibiotic‑only).
• Treatment: BPC-157 10 µg/kg/day via subcutaneous injection, pulsed 5 days on/2 days off, for 6 months.
• Readouts:
  • Gut permeability (FITC-dextran plasma flux).
  • Serum LPS‑binding protein, SCFA concentrations (GC‑MS).
  • Brain cytokines (ELISA), phospho‑S6K, LC3-II/I, SIRT1 (Western blot).
  • Cognitive and motor batteries monthly.
  • Survival monitoring until natural death.
• Analysis: Kaplan‑Meier survival curves with log‑rank test; two‑way ANOVA for biochemical endpoints; mediation analysis to test whether permeability changes mediate brain mTOR/SIRT1 shifts.

Potential Outcomes and Interpretation

If BPC-157 lowers gut leakiness, reduces brain inflammatory/mTOR signals, boosts autophagy, and extends lifespan—effects lost when microbiota are depleted—the hypothesis is supported, indicating that gut‑to‑brain signaling is a prerequisite for longevity interventions. Conversely, if BPC-157 fails to alter permeability or brain markers, or if lifespan improvement persists despite antibiotic‑induced microbiota loss, the gut‑centric mechanism is falsified, directing focus toward direct neuronal actions of the peptide.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC12937842/ [2] https://dailyemerald.com/173157/promotedposts/whats-new-in-peptide-research-longevity-gut-integrity-neurocognition-and-mitochondria/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC10053682/